Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Reply to: “correspondence about “Efficacy and safety of basiliximab”
Journal Information
Vol. 27. Issue 2.
(March - April 2022)
Share
Share
Download PDF
More article options
Vol. 27. Issue 2.
(March - April 2022)
Letters to the editor
Open Access
Reply to: “correspondence about “Efficacy and safety of basiliximab”
Visits
624
Mohamed Hashim
Corresponding author
msaadhh@hotmail.com

Corresponding author.
, Ayman Alsebaey, Amr Ragab, Hossam Eldeen Soliman, Imam Waked
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor:

We would like to thank the authors for their interest in our publication and their discussion.

Given the high incidence of renal impairment post liver transplantation, exploring methods to minimize or prevent this complication is of interest. The primary goal of our study was to evaluate the effectiveness and safety of basiliximab induction in liver transplantation to delay induction by CNI [1]. The pharmacokinetics of tacrolimus are influenced by many factors, including genetic variability, acute infections, liver dysfunction and interacting medications [2]. Nevertheless, the current recommendations from the clinical practice guidelines for the ideal tacrolimus level in adults after LT remain controversial. The American Association for the Study of Liver Diseases (AASLD) recommends a target tacrolimus blood trough level of 5–10 ng/mL three months after LT [3]. Other guidelines recommend that target tacrolimus blood trough levels be 6–10 ng/mL during the first month after LT and decrease to 4–8 ng/mL thereafter [4, 5]. In our institute, we are still using a higher level of tacrolimus, but recently we are going to put new protocols using lower levels based on recent guidelines.

Our observations highlight a need for long term follow up to evaluate the consequences of induction immunosuppression in liver transplant patients and define the indications and suitable patient profiles for basiliximab use. Finally, we fully agree with the need to study the effect of lower tacrolimus trough level on the outcomes after LT.

Financial support

The authors received no financial support to produce this manuscript.

References
[1]
M Hashim, A Alsebaey, A Ragab, HE Soliman, I. Weked.
Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: a single center study.
Ann Hepatol, 19 (2020), pp. 541-545
[2]
A Jantz, S Patel, W Suki, R Knight, A Bhimaraj, A. Gaber.
Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients.
Case Rep Transplant, 2013 (2013),
[3]
M.R. Lucey, N Terrault, L Ojo, J.E Hay, J Neuberger, E. Blumberg.
Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.
Liver Transpl, 19 (2013), pp. 3-26
[4]
J.M. Neuberger, W.O Bechstein, D.R. Kuypers, P Burra, F Citterio, S De Geest, et al.
Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in Transplantation (COMMIT) Group.
Transplantation, 101 (2017), pp. S1-S56
[5]
M Charlton, J Levitsky, B Aqel, J O'Grady, J Hemibach, M Rinella, et al.
International liver transplantation society consensus statement on immunosuppression in liver transplant recipients.
Transplantation, 102 (2018), pp. 727-743
Copyright © 2022. Fundación Clínica Médica Sur, A.C.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos